ARIAD

Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer

...903, a small-molecule dimerizer agent developed by ariad Pharmaceuticals, Inc. (Nasdaq: ARIA ). In this w...chnology underlying BP-GMAX-CD1 were licensed from ariad Pharmaceuticals, Inc. AP1903 is designed to bring...ted protein iCD40. AP1903 was previously shown by ariad to be well-tolerated with defined pharmacokinetics...

Lilly Reports Strong First-Quarter 2009 Results

... The Court of Appeals for the Federal Circuit in Washington, D.C. overturned a lower court decision and ruled in favor of the company in the case of ariad Pharmaceuticals et al. v. Eli Lilly and Company, holding that Ariad's patent claims purporting to cover Evista(R) and Xigris(R) are invalid. ...

Possible Viral Links to Lung Cancer Risk Uncovered

...ract of lung cancer patients and to explore the possibility for using HPV infection as a screening indicator for the disease. In the measles study, ariad and his team analyzed lung tissue samples taken from 65 Israeli lung cancer patients between the ages of 40 and 84. Ninety percent were smokers, and m...

ARIAD in Medical Technology

Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting

... sarcomas. In addition to its program in oncology, ariad is collaborating with Medinol Ltd to develop stent...jury following stent-assisted angioplasty. About ariad ariad is engaged in the discovery and development of bre...

ARIAD in Biological News

Viruses may play a role in lung cancer development

...m their cancer. "Measles virus is a ubiquitous human virus that may be involved in the pathogenesis of lung cancer," says lead author Prof. Samuel ariad from Soroka Medical Center in Beer Sheva, Israel. "Most likely, it acts in modifying the effect of other carcinogens and not as a causative factor by ...

ARIAD in Biological Technology

Gene Network Sciences Announces Michael Gilman as Board Member

...Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. From 1994 to 1999, Dr. Gilman held several positions at ariad Pharmaceuticals, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Gilman spent eight years on the scientific staff ...

New England Peptide Forms Scientific Advisory Board

...ter (Cambridge) and Pfizer's global chemistry leadership team. Sawyer also has held management and scientific positions in research and development at ariad Pharmaceuticals, Inc. (Cambridge), Parke-Davis/Warner-Lambert Company (Ann Arbor, Mich.), and The Upjohn Company (Kalamazoo, Mich.). Sawyer is the...

Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBC's Drug Discovery & Development of Innovative Therapeutics Conference

..., Harvard Medical School Companies also giving technical conference presentations in this cancer track include Alnylam Pharmaceuticals, Amgen, Inc., ariad Pharmaceuticals Inc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company, Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals,...

Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer

...ponsible for the early stage founding of Neurocrine and several other biotechnology companies such as Onyx Pharmaceuticals, Metra Biosystems, IDUN and ariad Pharmaceuticals. Dr. Gorman received his Ph.D. in Immunology from the University of California, Los Angeles and did further post-doctoral training at ...